益生菌制品对血脂水平干预疗效的Meta分析

摘要

目的 采用荟萃分析的方法评估益生菌制品对人群血脂水平的影响.方法 从PubMed、Co-chrane Library、Web of Science、EMBASE、中国期刊全文数据库、万方数据库、中文科技期刊全文数据库等数据库中检索关于应用益生菌制品对人群血脂水平进行干预的随机对照试验研究,利用RevMan 5.3.3软件对纳入研究结果进行Meta分析.结果 本研究共纳入18篇文献.Meta分析结果显示,与安慰剂组相比,益生菌干预组血清总胆固醇[均数差(mean difference,MD)=-0.2 mmol/L,95％可信区间(confidence intervals,CI):-0.28～-0.12 mmol/L]和低密度脂蛋白胆固醇(MD=-0.19 mmol/L,95％CI:-0.26～-0.13 mmol/L)下降更为明显(P<0.00001),2组高密度脂蛋白胆固醇及甘油三酯比较差异无统计学意义(P>0.05).高脂血症人群、体重指数在25～29.9 kg/m2的超重人群、干预期超过4周人群、接受肠道微生态制剂人群获益更大.结论 益生菌制品可有效下调血脂异常及健康人群的血清总胆固醇及低密度脂蛋白胆固醇水平,有望应用于血脂异常患者的动脉粥样硬化性心血管疾病一级及二级预防.%Objective To evaluate the efficacy of probiotic products on human serum lipid profiles, we conducted a meta-analysis. Methods Randomized, controlled clinical trials relating to interventional studies of probiotic products on human serum lipid profiles were obtained by search of electronic databases, such as PubMed, Cochrane Library, Web of Science, EMBASE, Chinses Pe-riodical Full Text Database, Wanfang Database, Full Text Database of Chinese Sci-Tech Periodical. Statistical analysis was performed with Review Manager 5. 3. 3. Results Eighteen randomized con-trolled trials were analyzed in our study. Meta-analysis results showed that the serum total cholesterol [mean difference(MD)=-0. 2 mmol/L, 95％ confidence intervals(CI): -0. 28— -0. 12 mmol/L] and low-density lipoprotein cholesterol ( MD=-0. 19 mmol/L, 95％CI:-0. 26 —-0. 13 mmol/L) were significantly decreased ( P<0. 00001) in probiotic intervention group compared with the placebo group, while high-density lipoprotein cholesterol and triglyceride had no significant differ-ence ( P>0. 05) . Patients with hyperlipidemia, overweight ( body weight index was 25—29. 9 kg/m2), receiving long-term intervention duration (>4 weeks) and intestinal micro-ecologic products got more benefit. Conclusion The probiotic products were effective in down-regulating the serum total cholesterol and low-density lipoprotein cholesterol levels in dyslipidemia patients and healthy in-dividuals. It is expected to be used in the primary and secondary prevention of atherosclerotic cardio-vascular diseases in patients with dyslipidemia.